LGND · Ligand Pharmaceuticals Incorpor
$308.30
+1.57% last session
End-of-day data · close of 2026-10-26
Market cap
$6B
Enterprise value
$6B
Trailing P/E
32.5
Forward P/E
25.8
Dividend yield
0.0%
Beta
1.01
Avg volume
0M
Employees
0K
Daily Change %
1.57%
5 Days Change
0.16%
10 Days Change
4.32%
30 Days Change
2.25%
60 Days Change
9.91%
Month to Day Change
1.84%
Year to Day Change
63.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LGND
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-25
Latest call per bank · past 12 months
Barclays
Overweight$345
+11.9% vs priceCitigroup
Buy$397
+28.8% vs priceRBC Capital
Outperform$345
+11.9% vs priceBank of America
Buy$388
+25.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-25 | Barclays | Initiates | Overweight | $0.00 → $345 |
| 2026-09-24 | HC Wainwright & Co. | Reiterates | Buy | $358 |
| 2026-09-23 | Citigroup | Maintains | Buy | $390 → $397 |
| 2026-08-14 | Leerink Partners | Initiates | Outperform | $0.00 → $330 |
| 2026-08-07 | RBC Capital | Maintains | Outperform | $340 → $345 |
| 2026-08-06 | HC Wainwright & Co. | Maintains | Buy | $289 → $358 |
| 2026-08-03 | Oppenheimer | Reiterates | Outperform | $285 → $326 |
| 2026-07-15 | RBC Capital | Maintains | Outperform | $262 → $340 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 4.8% above the 50-day MA ($294.13).
- bullish: Price vs 200-day MA: Trading 23.2% above the 200-day MA ($250.30).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.29) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($322.61).
LGND Price Chart
Loading chart for LGND…
Fundamentals
About Ligand Pharmaceuticals Incorpor
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.